DID HARVARD ABANDON 'ETHIC' FOR DOLLARS?

As university after university joined the patent chase, one academic institution stood out as a bulwark of ethical resolve—that is, until now. The university was Harvard, and even though the school began licensing inventions more than a decade ago, it earned its reputation as a bastion of purity because of landmark decision in 1981. At issue then was a controversial proposal involving molecular biologist Mark Ptashne, whose advances in recombinant DNA techniques were giving rise to new t

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

As university after university joined the patent chase, one academic institution stood out as a bulwark of ethical resolve—that is, until now. The university was Harvard, and even though the school began licensing inventions more than a decade ago, it earned its reputation as a bastion of purity because of landmark decision in 1981. At issue then was a controversial proposal involving molecular biologist Mark Ptashne, whose advances in recombinant DNA techniques were giving rise to new technologies. Rather than merely licensing his developments, Harvard considered helping Ptashne found a new company —a firm in which the university would then maintain a minority interest.

The case divided the faculty for months. And in the end, Harvard decided that the plan contained too many pitfalls. In his annual report for the 1979-80 school year, president Derek Bok explained that “in attempting to achieve practical results, the university must not endanger its ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies